Headquarters
611 FAIR OAKS AVE, OAK PARK, IL 60302-1737, US
OAK PARK, IL, US
IKAIKA THERAPEUTICS INC
From the company
Ikaika Therapeutics is a biotech company developing first-in-class anti-fibrotic antibodies, including IKN-001, which binds LTBP4 to prevent TGF-β activation and fibrosis accumulation. Its pipeline targets fibrotic diseases including muscular dystrophy, based on genetic research identifying LTBP4 as a driver of fibrotic disease severity.
Products & services offered
Capabilities 4
Classifications
- Ownership classifications (2)
- Woman Owned Business, Woman Owned Small Business
Facilities
Send your requirements
Quantities, certifications, and timing.